SCIENTIFIC LETTER

Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion

Maria-Eleni Vazakidou

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Search for more papers by this author

Sofia Magkouta,

Sofia Magkouta

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Search for more papers by this author

Charalambos Moschos,

Charalambos Moschos

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Search for more papers by this author

Ioannis Kalomenidis,

Corresponding Author

Ioannis Kalomenidis

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Correspondence: Ioannis Kalomenidis, ‘Marianthi Simou Lab’, 3 Ploutarchou Street, 10675, Athens, Greece. Email: [email protected]Search for more papers by this author

Maria-Eleni Vazakidou,

Maria-Eleni Vazakidou

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Search for more papers by this author

Sofia Magkouta,

Sofia Magkouta

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Search for more papers by this author

Charalambos Moschos,

Charalambos Moschos

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Search for more papers by this author

Ioannis Kalomenidis,

Corresponding Author

Ioannis Kalomenidis

1st Department of Critical Care and Pulmonary Services, School of Medicine, Evangelismos Hospital, University of Athens, Athens, Greece

Correspondence: Ioannis Kalomenidis, ‘Marianthi Simou Lab’, 3 Ploutarchou Street, 10675, Athens, Greece. Email: [email protected]Search for more papers by this author

First published: 02 July 2013

https://doi.org/10.1111/resp.12151

Citations: 3

Conflict of Interest Statement

Dr Ioannis Kalomenidis, as group leader, has received research funding from Wyheth Hellas SA for this and other projects.

Share a link

Email
Wechat
Bluesky

Abstract

The impact of temsirolimus was investigated in a murine model of malignant pleural effusion (MPE) created with intrapleural injection of Lewis Lung Cancer (LLC) cells. Temsirolimus (1 or 20 mg/kg) did not affect the pleural fluid volume or the number of pleural tumour foci. In addition, temsirolimus did not affect vascular endothelial growth factor expression by LLC cells in vitro. In conclusion, temsirolimus did not curtail experimental lung-adenocarcinoma-induced MPE.

References

1 Zaytseva YY, Valentino JD, Gulhati P et al. mTOR inhibitors in cancer therapy. Cancer Lett. 2012; 319: 1–7.
10.1016/j.canlet.2012.01.005
CAS PubMed Web of Science® Google Scholar
2 Ohara T, Takaoka M, Toyooka S et al. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells. Cancer Sci. 2011; 102: 1344–1349.
10.1111/j.1349-7006.2011.01967.x
CAS PubMed Web of Science® Google Scholar
3 Roberts ME, Neville E, Berrisford RG et al. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. BTS Pleural Disease Guideline Group. Thorax 2010; 65: ii32–40.
10.1136/thx.2010.136994
PubMed Web of Science® Google Scholar
4 Kim YK, Lee HY, Lee KS et al. Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic implications. Radiology 2011; 260: 568–574.
10.1148/radiol.11110053
PubMed Web of Science® Google Scholar
5 Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am. J. Respir. Crit. Care Med. 2012; 186: 487–492.
10.1164/rccm.201203-0465PP
PubMed Web of Science® Google Scholar
6 Stathopoulos GT, Zhu Z, Everhart MB et al. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am. J. Respir. Cell Mol. Biol. 2006; 34: 142–150.
10.1165/rcmb.2005-0130OC
CAS PubMed Web of Science® Google Scholar
7 Wislez M, Spencer ML, Izzo JG et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res. 2005; 65: 3226–3235.
10.1158/0008-5472.CAN-04-4420
CAS PubMed Web of Science® Google Scholar
8 Stathopoulos GT, Kalomenidis I. Animal models of malignant pleural effusion. Curr. Opin. Pulm. Med. 2009; 15: 343–352.
10.1097/MCP.0b013e32832af07c
PubMed Web of Science® Google Scholar
9 Yano S, Shinohara H, Herbst RS et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of Vascular Endothelial Growth Factor/Vascular Permeability Factor by human lung cancer cells. Am. J. Pathol. 2000; 157: 1893–1903.
10.1016/S0002-9440(10)64828-6
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume19, Issue2

February 2014

Pages 290-292

Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Mammalian target of rapamycin (mTOR) inhibition does not prevent lung adenocarcinoma-induced malignant pleural effusion

Abstract

References

Citing Literature

References

Related

Information